|Awarded On||February 21, 2019|
|Title||A first-in-class anti-VISTA monoclonal antibody for the treatment of MDSC-mediated suppression of anti-tumor immunity in solid tumors and lymphomas|
|Program||Product Development Research|
|Award Mechanism||Company Relocation|
|Institution/Organization||Hummingbird Bioscience, Incorporated|
|Principal Investigator/Program Director||Piers Ingram|
|Cancer Sites||All Sites|
Hummingbird Bioscience, a highly innovative biotech company, with facilities in Singapore and South San Francisco, is applying for a CPRIT Relocation grant to move to Texas. The company has developed a new cancer therapy, HMBD-002-V4, for patients who are resistant to cancer immuno-oncology (IO) drugs.
FDA-approved IO drugs that harness the power of the body’s immune system to fight cancer have made rapid advances in treating patients with cancers who previously had very few options. This includes patients with melanoma, non-small cell lung cancer, kidney and bladder cancer and several others. However, as many as 70% of these patients develop resistance and their cancer progresses, and they ...